Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases
https://doi.org/10.21516/2072-0076-2023-16-4-141-146
Abstract
Purpose: to evaluate the effect of a new antiallergic drug epinastine in the treatment of seasonal conjunctivitis as manifested in clinical cases.
Materials and methods. 37 people (22 men and 15 women) were observed during spring exacerbation of the allergic conjunctivitis, from mid-March to the end of June. Indicators of the dynamics of subjective complaints, duration of treatment, clinical effectiveness, were thoroughly recorded; we also assessed how easy it was to stop using the treatment when the condition of the ocular surface returned to normal.
Results. We identified four groups of patients depending on the course of the disease, clinical manifestations, and response to epinastine therapy. For each group, we analyze a most informative clinical case.
Conclusions. In all of the cases, epinastine instillations brought about a quick and stable reduction of itching and eye discomfort, as well as normalization of the clinical condition of the conjunctiva.
About the Author
E. V. Yani
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Elena V. Yani — Cand. of Med. Sci, head of the department of infectious and allergic eye diseases
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia
References
1. Terekhova E.P. Allergic conjunctivitis: textbook. GBOU DPO “Russian Medical Academy of Postgraduate Education”. Moscow: GBOU DPO RMAPO, 2014 (In Russ.).
2. Neroev V.V., Vakhova E.S. Diseases of the conjunctiva. National Guide for Ophthalmology. GEOTAR-Media, 2017 (In Russ.).
3. Tasaka K, Akagi M, Izushi K, Aoki I. Antiallergic effect of epinastine: the elucidation of the mechanism. Pharmacometrics. 1990; 39: 365–73.
4. Fujishima H, Ohashi Y, Takamura E. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. Ann Allergy Asthma Immunol. 2014; 113: 476–81. https://doi.org/10.1016/j.anai.2014.07.007
5. Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci. 2001 Feb; 42 (2): 321–7. PMID: 11157861.
6. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005; 65 (2): 215–28. doi: 10.2165/00003495-200565020-00004
7. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006 Dec; 32 (6): 272–6. doi: 10.1097/01.icl.0000224360.10319.b1
8. Wolff SC, Brubaker K, Navratil T, et al. Evaluation of muscarinic receptor antagonism by antihistamines. The Journal of Allergy and Clinical Immunology. 2007; 119 (1): S153. doi: https://doi.org/10.1016/j.jaci.2006.11.535
Review
For citations:
Yani E.V. Using a new antiallergic drug Epinepta® in the treatment of seasonal allergic conjunctivitis. Clinical cases. Russian Ophthalmological Journal. 2023;16(4):141-146. (In Russ.) https://doi.org/10.21516/2072-0076-2023-16-4-141-146
Views:
402
Email this article 